Benefits
Antioxidant status markers in one small trial
In a 3-week placebo-controlled crossover trial in 28 adults, 15 mg a day of hydroxytyrosol from elaVida capsules raised total antioxidant status and thiol groups and lowered malondialdehyde, a marker of fat oxidation, versus each phase's starting values. Thiols and malondialdehyde did not change on placebo. This is one small trial.
Oxidized LDL: unchanged in its own trial; lower with a similar extract
In elaVida's 3-week trial, oxidized LDL, total cholesterol, HDL and triglycerides did not change, and LDL cholesterol rose slightly in both the hydroxytyrosol and placebo phases. A 16-week trial of a different olive fruit extract (Hytolive®) at the same 15 mg a day lowered oxidized LDL versus placebo without changing blood lipids. This is limited evidence with mixed results.
Mechanism of action
Interrupting fat oxidation (lab evidence)
Hydroxytyrosol's catechol structure lets it neutralize peroxyl radicals and break the chain reactions that oxidize fats, which is how it protects lipids in laboratory tests. Whether this lowers oxidized LDL in people taking elaVida has not been shown; its own trial found no change.
Free-radical scavenging
Hydroxytyrosol's structure makes it an effective scavenger of free radicals in laboratory studies.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial. Two enteric-coated capsules a day, each with 7.5 mg of hydroxytyrosol from elaVida olive extract in an olive oil base, for 3 weeks, with a washout and 3 weeks of placebo (the same capsule without the extract) in the other phase. Each phase was compared with its own starting values. Funded by the Italian agriculture ministry; authors reported no conflicts. (Colica et al. 2017, Oxidative Medicine and Cellular Longevity)
28 adults aged 18 to 65 (average age 32) with normal weight, overweight or metabolically healthy obesity.
During the hydroxytyrosol phase, total antioxidant status and thiol groups rose, malondialdehyde, nitrite and nitrate fell, SOD1 gene expression rose, and hydroxytyrosol was measurable in plasma; thiols, malondialdehyde, nitrite and nitrate did not change on placebo. Oxidized LDL, total cholesterol, HDL and triglycerides did not change, and LDL cholesterol rose slightly in both phases. Weight (down 0.46%), body fat percentage and the suprailiac skinfold fell slightly. The paper tests before versus after within each phase, not hydroxytyrosol directly against placebo.
Randomized, double-blind, placebo-controlled trial of capsules giving 7.5 mg of hydroxytyrosol plus 10 mg of vitamin E a day for 4 months (doses from the trial registration, NCT02842567). The abstract and registration do not name the hydroxytyrosol source; a later paper by other researchers states it was elaVida. (Nobili et al. 2019, Antioxidants & Redox Signaling)
80 adolescents with biopsy-confirmed nonalcoholic fatty liver disease; 70 completed.
The hydroxytyrosol plus vitamin E group showed lower insulin resistance, triglycerides and oxidative stress markers and a lower ultrasound fat grade in the liver after 4 months. Because vitamin E was in the same capsule, the results cannot be credited to hydroxytyrosol alone, and this was a study of a medical condition, not of healthy people.
Randomized, double-blind, placebo-controlled parallel trial of one capsule a day giving 15 mg of hydroxytyrosol for 16 weeks. The trial registration (NCT06295913) identifies the capsule as Hytolive®, a different olive fruit extract, so this is class evidence, not an elaVida study. (Moratilla-Rivera et al. 2025, Clinical Nutrition)
Adults aged 40 to 70 with overweight and prediabetes; 52 randomized, 49 completed.
Compared with placebo, hydroxytyrosol lowered oxidized LDL (the primary outcome, p = 0.045), protein carbonyls and 8-OHdG, prevented a fall in total antioxidant status and GPx activity, and lowered IL-6 (p = 0.05). Blood lipids, body measurements and lifestyle measures did not change. No adverse events were observed.